Intravitreal botulinum toxin implant

A biodegradable ocular implant for treating a medical condition of the eye, the biodegradable ocular implant comprising:

• (a) a biodegradable carrier, and;
• (b) a botulinum neurotoxin associated with the biodegradable carrier, thereby forming a biodegradable ocular implant, wherein the implant releases no more than about 15 percent of the botulinum neurotoxin from the carrier during the first twenty four hours after implantation of the biodegradable implant into an eye of a patient and the implant releases more than about 80 percent of the botulinum neurotoxin from the carrier within the first twenty eight days after implantation of the implant into an eye of a patient.

A method for treating an ocular disease, the method comprising the step of implanting into an eye of a patient a biodegradable implant comprising a botulinum neurotoxin associated with a carrier.

A method for treating an ocular disease, the method comprising the step of implanting into the vitreous cavity of an eye of a patient a biodegradable implant comprising a botulinum neurotoxin associated with a carrier, wherein the step of implanting the biodegradable implant results in an approximately 10-fold less concentration of the botulinum toxin in the aqueous humor of the eye into which the implant was implanted as compared to the concentration of the botulinum toxin in the vitreous humor of the eye into which the implant was implanted.